Ovid Therapeutics Inc.

Listed Company

OVIDCIK 0001636651NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$7.25M

Net Income

$-17.40M

Total Assets

$150.93M

Equity

$130.66M

Shares Out

131.87M

Op. Cash Flow

$-38.30M

Business

Ovid Therapeutics Inc. is a biopharmaceutical company developing precision small‑molecule medicines for central nervous system disorders driven by neuronal hyperexcitability. It offers clinical and preclinical drug candidates including OV329 (a GABA‑AT inhibitor), a KCC2 direct activator portfolio (OV350, OV4071, OV4041) and OV888 (a ROCK2 inhibitor) aimed at seizures, drug‑resistant epilepsies and psychosis associated with neurodegenerative synuclein diseases. Key business areas include research and development, clinical development programs and licensing/collaboration partnerships. It advances programs via global clinical trials, academic collaborations, outsourced manufacturing and strategic commercialization or regional licensing channels.

Summary from filing dated 2025-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	7	566,000	392,000	2	208
Research and development	26	37	29	25	47
General and administrative	24	26	31	32	37
Total operating expenses	50	62	60	57	84
Loss from operations	−42	−62	−59	−56	124
Other income (expense), net	25	35	7	1	−45,690
Loss before provision for income taxes	−17	−26	−52	−54	124
Provision for income taxes	0	0	0	0	1
Net loss	−17	−26	−52	−54	123

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	13	26	27	45	188
Marketable securities	56	27	79	84	0
Prepaid expenses and other current assets	5	3	4	2	3
Total current assets	74	56	110	131	190
Marketable securities - noncurrent	21	0	—	—	—
Long-term equity investments	42	21	—	—	—
Restricted cash	2	2	2	2	2
Right-of-use asset, net	12	13	14	15	0
Property and equipment, net	252,000	433,000	769,000	1	242,757
Other assets	0	92,000	210,000	261,191	260,126
Total assets	151	92	144	155	195
Accounts payable	2	3	4	2	7
Accrued expenses	5	6	7	5	8
Current portion, lease liability	1	1	1	533,946	0
Total current liabilities	8	11	11	7	15
Lease liability	12	13	15	16	0
Total liabilities	20	24	56	23	15
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 0 and 1,250 shares issued and outstanding at December 31, 2025 and 2024, respectively	0	0	0	1	1
Common stock, $0.001 par value; 315,000,000 and 125,000,000 shares authorized; 130,184,353 and 71,009,866 shares issued and outstanding at December 31, 2025 and 2024, respectively	130,000	71,000	71,000	70,467	70,359
Additional paid-in-capital	452	372	366	358	351
Accumulated other comprehensive loss	−202,000	−35,000	1,000	−42,187	0
Accumulated deficit	−322	−304	−278	−226	−171
Total stockholders equity	131	68	88	132	180
Total liabilities and stockholders equity	151	92	144	155	195

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Change in fair value of royalty monetization liability	0	−30	0	—	—
Unrealized gain on equity investments	−21	−3	−2	454,811	0
Change in accrued interest and accretion of discount on marketable securities	−695,000	−3	−2	−1	—
Stock-based compensation expense	5	6	7	7	5
Depreciation and amortization expense	273,000	613,000	568,000	512,505	237,079
Noncash operating lease expense	1	1	1	869,100	0
Change in lease liability	−1	−1	−534,000	936,927	—
Prepaid expenses and other current assets	−2	899,000	−1	109,292	40,503
Accounts payable	−1	−512,000	2	−5	2
Accrued expenses	−1	−537,000	2	−3	−4
Net cash used in operating activities	−38	−56	−46	−55	119
Purchase of marketable securities	−92	−73	−112	−173	0
Sales/maturities of marketable securities	42	128	120	90	0
Purchases of property and equipment	0	−71,000	−40,000	−1	−184,008
Software development and other costs	0	−90,000	−97,000	−194,397	−5,400
Net cash (used in) provided by investing activities	−50	55	−3	−88	−2
Proceeds from private placement financing, net of transaction costs	75	0	—	—	—
Proceeds from exercise of options and employee stock purchase plan	91,000	622,000	535,000	180,658	925,396
Net cash provided by financing activities	75	622,000	31	180,658	904,082
Effect of exchange rates on cash, cash equivalents and restricted cash	−167,000	0	—	—	—
Net decrease in cash, cash equivalents and restricted cash	−13	−740,000	—	−143	118

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro